Pipeline

Program

Product

Target

Indications

IND

NJA-001*

iPS-ɑβ T cell

GPC3 TCR

HCC, CRC, NSCLC

2026

NJA-201*

iPS-NK cell

CD19 CAR

Autoimmune diseases

2026

NJA-301

iPS-ɑβ T cell

IL13Ra2 & EGFR CAR

Glioblastoma

2028

*AMED grant funded program

Why NJA?

Sharing its name with the Japanese term for stealth assassin or ninja, Shinobi has aptly designated its iPS pipeline 'NJA.'

Technology

Evasion

NJA cells are engineered with immune-evasive properties, rendering them invisible to the body’s immune system. By avoiding detection and rejection by T cells, innate immune cells, and antibodies, NJA enables safer, scalable, and re-doseable allogeneic therapies.

Armoring

NJA cells are further enhanced with advanced genetic modifications to withstand hostile environments, such as the immunosuppressive tumor microenvironment. These enhancements ensure delivery of molecular payloads, in the face of precarious conditions.

“Shinobi’s Katana platform has the potential to offer treatment options for most cancer patients when combined with Anocca’s ability to systematically unlock the largely unexploited landscape of TCR-T targets.”

Reagan Jarvis

CEO and Co-Founder of Anocca

Corporate
Partnerships

Shinobi partners with top-tier institutions to consistently source and advance groundbreaking research in immune evasive iPSC-derived cell therapies.

“Reducing the production time and cost of cell therapies must be done in a manner that does not compromise safety or efficacy, and we are thrilled to see the Japanese biotech and engineering communities coming together to make that happen.”

Yuki Kusumi

Representative Director and President of Panasonic Holdings Corporation

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology